14), (18), (19), (21) Only early radical surgery and postoperative polychemotherapy
can achieve success.
In contrast patients with high-risk disease may be treated with polychemotherapy
along with an anti-CD20 monoclonal antibody.
Remission induction consists of 64 days of intensive polychemotherapy
with vincristine and doxorubicin (days of administration: 8, 15, 22, and 29, specifying "days from diagnosis"), prednisolone (days 1 through 38), native l-asparaginase (administered 3 times daily for 8 consecutive days, starting from day 12), cyclophosphamide (days 36 and 64), oral 6-mercaptopurine (days 36 through 63), cytosine-arabinoside (administered in 4 courses over 4 days each on days 38 through 41, 45 through 48, 52 through 55, and 59 through 62), and intrathecal MTX (days 1, 12, 33, 45, and 59).
This was followed by high-dose polychemotherapy
with mitoxanthrone, cyclophosphamide, and vinblastine or carboplatin with hematopoietic support as described elsewhere (Gluck, Arnold, Ho & Nabholtz, 1995).
breast cancer, therapeutics, adjuvant treatment, cytotoxic, antiangiogenesis, vaccines, monoclonal antibodies, aromatase inhibitors, Aromasin, Femara, tamoxifen citrate, extended adjuvant setting, antiemetics, neutropenia, chemosensitizing agents, chemotherapy, polychemotherapy
, monotherapy, taxanes, vinca alkaloids, monoclonal antibodies, non-cross resistant drugs, research, information, market, trends, technology, service, forecast.
of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
combined with G-CSF mobilized donor buffy coat transfusion for granulocytic sarcoma after allogeneic BMT for AML.
Lemmers NW, Gels ME, Sleijfer DT, et al: Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy
Additionally, 47 patients had received adjuvant polychemotherapy
with procarbazine, lomustine, and vincristine.
As part of a treatment regimen, the drug delivery system will be implanted at the site of a surgically removed tumor and used to deliver sustained doses of polychemotherapy
to surrounding tissues to eliminate any remaining tumor cells and, then, persist for a period of time afterward to act as a scaffold to assist the repair of healing tissue.
Five courses of polychemotherapy
were administered accordingly (sequential proMECE/CytaBOM: cyclophosphamide, epirubicin, etoposide, prednisone, cytarabine, vincristine, bleomycin, and methotrexate).
The most recent meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) has shown that administration of anthracycline-based polychemotherapy
for around 6 months reduces the annual breast cancer death rate by about 38% for those aged <50 years and by approximately 20% for those aged 50-69 years at the time of diagnosis.